U.S. pharma large copyright scrapped two experimental weight loss products last calendar year—a after-everyday capsule, lotiglipron, as a consequence of elevated liver enzymes and also a 2 times-day-to-day capsule, danuglipron, as a result of solid Negative effects—but CEO Albert Bourla has said the company is determined to “play and win” i